India patent office rejects Gilead's Sovaldi application

The Indian Patent Office rejected an application from Gilead Sciences Inc. (NASDAQ:GILD) for a patent covering HCV drug Sovaldi sofosbuvir.

The patent office issued a Harvoni sofosbuvir/ledipasivir for distribution in 91 developing countries (see BioCentury Extra, Sept. 15, 2014). ...